Kaiku Health, the developer of digital health intervention platform in oncology, has received the Digi-HTA recommendation of use. The Digi-HTA is a criteria tool for assessing digital healthcare services’ (eg. mobile apps, AI solutions, and robotics) suitability for use in healthcare. The recommendation states that: “The Kaiku Health service is suitable for monitoring the well-being...
Increasing the understanding behind treatment response and immune-related adverse events in cancer patients treated with immune checkpoint inhibitor therapies Kaiku Health and Oulu University Hospital (OYS) aim to increase the understanding behind treatment benefit and onset of complex immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapies. The findings from this study conducted...
Kaiku Health, the developer of digital health intervention platform in oncology, adds medical expertise and years of experience in oncology and hematology with Dr. Mari Metso-Lintula joining the team as Medical Director. Dr. Metso-Lintula is an experienced oncologist and hematologist with a background in the medical device industry and electronic patient-reported outcomes. Her responsibilities at...
Kaiku has continued its pioneering research and efforts to find potential ways to improve safety and quality of life of cancer patients treated with immune checkpoint inhibitor (ICI) therapies. ICIs can be associated with severe adverse events which may occur even after treatment discontinuation. Research conducted in collaboration between Kaiku Health and the Oulu University...
Kaiku Health will present two scientific abstracts at the ESMO Virtual Congress 2020. The research has been conducted in collaboration with Oulu University Hospital and it investigates combining machine learning, patient-reported symptom data and lab measurements to analyse treatment response and predict the onset of immune-related adverse events in immune checkpoint inhibitor therapies. The two...